 We hypothesize that the addition of cetuximab to twice weekly paclitaxelcisplatin concurrent chemoradiotherapy TP-CCRT as the adjunctive therapy before esophagectomy or as a definitive CRT would improve the therapeutic efficacy of TP-CCRT in patients with loco-regional esophageal squamous cell carcinoma ESCC. 